Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 44Medulloblastoma 9Lymphoma 9Sarcoma 8Brain Neoplasms 8Neuroectodermal Tumors, Primitive, Peripheral 7Central Nervous System Neoplasms 7Rhabdomyosarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Wilms Tumor 5Sarcoma, Ewing 5Leukemia 5Ganglioneuroblastoma 5Burkitt Lymphoma 5Astrocytoma 5Rhabdoid Tumor 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hepatoblastoma 4Glioma 4Dendritic Cell Sarcoma, Interdigitating 4Testicular Neoplasms 3Retinoblastoma 3Recurrence 3

Interventions

Cyclophosphamide 10Temozolomide 8X-Rays 7Specimen Handling 7Irinotecan 7Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Filgrastim 6Carboplatin 5Biopsy 5fludarabine 4Nuclear Medicine Department, Hospital 4olaparib 3fludarabine phosphate 3etoposide phosphate 3dinutuximab 3Zoledronic Acid 3Oxaliplatin 3Nivolumab 3Ifosfamide 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Etoposide 3Docetaxel 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2lorukafusp alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Melphalan × CNS × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡